Revolutionary Procedure: Injecting Slurry to Regenerate a New Liver in Patients
LyGenesis, a biotech company, has achieved a breakthrough by dosing a human patient with liver cells in a Phase 2a clinical trial to transform a lymph node into a functional liver. The treatment offers hope for the millions suffering from end-stage liver disease, as transplants are limited. By utilizing lymph nodes as bioreactors, the treatment aims to alleviate the organ supply-demand imbalance. Uncertainties remain, but the potential impact on patients is promising.